Experimental drug lowers lipoprotein(a), a suspect in heart attacks

Research we're watching

Published: April, 2020

A new kind of drug given by injection can lower blood levels of lipoprotein(a), or Lp(a), a fatty particle linked to a heightened risk of heart attack and narrowing of the aortic valve, according to a study published January 1 in the New England Journal of Medicine.

Up to one in five people has a very high level of Lp(a), which is nearly completely determined by a person's genes. Lp(a) particles are similar to the better-known LDL cholesterol particles but with an extra protein coiled around each particle.

The drug, known as APO(a)-LRx, works by silencing the gene that causes liver cells to make Lp(a). The study compared different doses of the drug to a placebo injection in 286 people with cardiovascular disease whose Lp(a) levels were 60 milligrams per deciliter (mg/dL) or higher. Normal levels are 30 mg/dL or lower.

The highest dose of the drug lowered Lp(a) levels by 80%, compared with a 6% drop in people who got the placebo. A study investigating the drug's ability to lower the risk of heart attacks and other cardiovascular problems is currently under way.

Image: sturti/Getty Images

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.